Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Official title: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
192
Start Date
2026-12
Completion Date
2028-03
Last Updated
2026-08-27
Healthy Volunteers
No
Conditions
Interventions
Orforglipron
Administered orally.
Placebo
Administered orally.
Locations (13)
Sichuan Provincial People's Hospital
Chengdu, China
Zhujiang Hospital
Guangzhou, China
The first Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
The Second People's Hospital of Hefei
Hefei, China
Jinan Central Hospital
Jinan, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, China
Jiangxi Provincial People's Hospital
Nanchang, China
Nanjing First Hospital
Nanjing, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
Shanghai Sixth People's Hospital
Shanghai, China